ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · ESMO Open · 2026-06-25

Secondary analysis of the phase III ABC-06 trial in advanced biliary cancer: raised CA19-9, CEA and CA125 each independently predicted shorter overall survival (n=120); time to QoL deterioration did not differ between ASC + FOLFOX and ASC alone (n=76; aHR 0.97).

Secondary analysisn = 162
Lamarca et al. Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.